Godavari Biorefineries Limited has successfully secured a patent from the Japan Patent Office for its application No. 2022-568620. The patent pertains to the use of specific compounds for treating viral infections by inhibiting V-ATPase activity in cells. This grant strengthens the company's intellectual property portfolio in Japan and validates its research capabilities in the antiviral therapeutics space. While the immediate revenue impact is not specified, it enhances the company's long-term competitive positioning in global biochemical markets.

• Japan Patent Office granted patent No. 2022-568620 titled 'Use of Compounds for Treating Viral Infections'
• The invention focuses on inhibiting V-ATPase activity in cells to treat viral infections
• Strengthens global intellectual property protection and adds value to the antiviral therapeutics portfolio
• The disclosure was made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Godavari Biorefineries reported a strong Q3 FY26 with Profit Before Tax (PBT) surging 152% YoY to ₹21.4 crores, despite modest revenue growth of 2.5%. The company achieved significant margin expansion, with EBITDA margins rising 97 bps to 9.8%, supported by a 48% reduction in finance costs and a better product mix in bio-based chemicals. Management highlighted a ₹325 crore capex plan through FY29, aimed at tripling EBITDA by focusing 75% of investment on high-margin chemicals. The consumer brand 'Jivana' also hit a milestone, crossing ₹100 crores in revenue for the 9-month period.

• Q3 PBT before exceptional items grew 152.2% YoY to ₹21.4 crores driven by operating leverage.
• EBITDA increased by 13.8% to ₹45.1 crores with margins expanding to 9.8%.
• Finance costs declined by 48% YoY, reflecting improved cash flows and balance sheet strengthening.
• Bio-based chemicals EBITDA margin improved significantly to 7.7% from 4.5% in the previous year.
• Consumer brand 'Jivana' achieved a revenue milestone of ₹100 crores during 9M FY26.

Godavari Biorefineries reported a 43.2% YoY increase in consolidated Profit After Tax (PAT) for Q3 FY26, reaching ₹8.25 crore. Revenue from operations grew slightly to ₹459.85 crore, while the company saw a significant reduction in finance costs, which dropped to ₹10.21 crore from ₹18.85 crore YoY. For the nine-month period ended December 2025, the company narrowed its consolidated loss to ₹49.36 crore from a loss of ₹95.34 crore in the previous year. The company also issued a correction regarding a deferred tax entry in its nine-month results, clarifying it as Nil.

• Q3 FY26 PAT increased by 43.2% YoY to ₹8.25 crore from ₹5.76 crore in Q3 FY25.
• Finance costs for the quarter significantly reduced by 45.8% YoY to ₹10.21 crore.
• 9M FY26 revenue from operations grew 10.3% YoY to ₹1,423.84 crore.
• Consolidated loss for 9M FY26 narrowed substantially to ₹49.36 crore from ₹95.34 crore YoY.
• Profit before exceptional items and tax for Q3 FY26 stood at ₹21.37 crore compared to ₹8.47 crore in the same quarter last year.

Godavari Biorefineries reported a consolidated revenue of ₹459.85 crore for Q3 FY26, a 2.8% increase compared to ₹447.27 crore in the same quarter last year. The company's net profit for the quarter surged by 43.2% YoY to ₹8.25 crore, up from ₹5.76 crore in Q3 FY25. On a nine-month basis, while the company remains in a net loss of ₹49.36 crore, this is a significant improvement from the ₹95.34 crore loss reported in the previous year's corresponding period. A notable positive is the sharp reduction in finance costs, which dropped to ₹10.21 crore in Q3 FY26 from ₹18.85 crore in Q3 FY25.

• Q3 FY26 Revenue from operations grew 2.8% YoY to ₹459.85 crore.
• Net Profit (PAT) for the quarter increased 43.2% YoY to ₹8.25 crore from ₹5.76 crore.
• Finance costs saw a sharp decline of 45.8% YoY, falling to ₹10.21 crore in Q3 FY26.
• 9M FY26 losses narrowed significantly to ₹49.36 crore compared to a loss of ₹95.34 crore in 9M FY25.
• The company reported an exceptional item expense of ₹7.88 crore during the current quarter.

Godavari Biorefineries reported a 152.2% YoY surge in PBT (before exceptional items) to ₹21.4 crore for Q3 FY26, driven by operating leverage and a 46% reduction in finance costs. Total income for the quarter grew 2.5% YoY to ₹461.9 crore, while EBITDA margins expanded by 97 basis points to reach 9.8%. The Bio-based Chemicals segment showed strong performance with a 76.7% YoY increase in EBITDA, and the 'Jivana' consumer brand crossed ₹100 crore revenue in 9M FY26. Despite a 56.6% drop in Ethanol segment EBITDA, the company is expanding its grain-based ethanol capacity, expected to be commissioned in Q1 FY27.

• Q3 FY26 PBT (before exceptional items) rose 152.2% YoY to ₹21.4 crore.
• EBITDA grew 13.8% YoY to ₹45.1 crore with margins improving to 9.8%.
• Finance costs significantly reduced by 46% YoY, improving overall cash flow.
• Bio-based Chemicals EBITDA increased 76.7% YoY to ₹10.9 crore.
• Jivana consumer brand crossed ₹100 crore revenue in 9M FY26.

Godavari Biorefineries Limited (GBL) has announced a strategic partnership with London-listed Synthomer plc to develop bio-based alternatives to fossil-based monomers. Under this collaboration, GBL will supply bio-based butanol to enable Synthomer to commercialize bio-based butyl acrylate. This move targets the growing global demand for sustainable, lower-carbon chemical solutions and leverages GBL's integrated biorefinery capabilities. The partnership provides GBL with a significant global platform through Synthomer's 29 manufacturing sites across Europe, North America, and Asia.

• Strategic partnership with Synthomer to commercialize bio-based butyl acrylate using GBL's bio-based butanol.
• Collaboration focuses on transitioning the chemical industry away from fossil-based materials toward green chemistry.
• Synthomer is a major global player with approximately 3,900 employees and 29 manufacturing sites worldwide.
• The initiative aligns with GBL's strategy to expand its specialty bio-based chemicals portfolio for international markets.

Godavari Biorefineries Limited (GBL) has incorporated Sathgen Therapeutics LLC, a wholly owned step-down subsidiary in Princeton, New Jersey. This strategic move aims to accelerate GBL's clinical-stage biotechnology programs and facilitate the global out-licensing of intellectual property. The subsidiary will focus on novel molecules targeting triple-negative breast cancer (TNBC), leveraging patents already secured in major markets including the US, Europe, and China. This expansion positions GBL to transition from a generic-focused manufacturer to a player in original drug discovery and high-value clinical partnerships.

• Incorporation of Sathgen Therapeutics LLC in Princeton, USA, as a wholly owned step-down subsidiary.
• Secured patents in the US, Europe, and China for novel compounds targeting cancer stem cells and TNBC.
• Appointment of Dr. Padmaja Ganpathy as CEO and Dr. Sendurai Mani as CSO for the U.S. entity.
• Formation of a Scientific Advisory Board featuring global oncology experts Dr. Razelle Kurzrock and Dr. Massimo Cristofanilli.
• Strategic focus on global out-licensing of IP to accelerate drug-development programmes.

Godavari Biorefineries Limited has received a United States patent for "COMPOUNDS FOR THE INHIBITION OF UNREGULATED CELL GROWTH" in the anti-cancer research segment. The patent covers novel chemical compounds that inhibit unregulated cell growth, targeting cancer stem cells. These compounds have shown potential for treating cancers like breast and prostate cancer. This development strengthens the company's intellectual property portfolio in a promising area of cancer research.

• US Patent granted for "COMPOUNDS FOR THE INHIBITION OF UNREGULATED CELL GROWTH"
• Patent application number is 17/415,676
• PCT Filed on Dec. 16, 2019
• Priority Data: Dec. 17, 2018 (IN) 201821047582